Upon graduating from Texas A&M, Blake accepted a one-year Pre-doctoral Fellowship position with the Texas Heart® Institute (THI) at St. Luke’s Episcopal Hospital in the Texas Medical Center. As a Fellow and research intern, Blake divided his time between Comparative Cardiovascular Pathology and the Cullen Cardiovascular Research Laboratories where he completed qualifications for FDA preclinical validation studies (GLP –Good Laboratory Practices).
At the conclusion of his fellowship, THI offered Blake a Senior Research Assistant position where he became a member of a cardiovascular surgical research team investigating a variety of preclinical and clinical research endeavors including the Jarvik 2000 FlowMaker®, the AbioCor™ implantable replacement heart (the first completely self-contained total artificial heart), mechanical replacement valves, stem cell regeneration of ischemic myocardium, BioGlue® surgical adhesive, and near-infrared spectroscopy to monitor regional cerebral oxygen saturation during infrarenal aortic cross-clamping.
Blake’s research culminated in a study evaluating antibody inhibition of the body’s inflammation response to cardiopulmonary bypass which was conducted in the baboon model. When not in the surgical labs, Blake was part of a cardiovascular pathology research team integral in designing software used to microscopically evaluate atherosclerotic plaque and coronary stenosis.
Blake has co-authored two medical manuscripts accepted for publication, one in The Annals of Thoracic Surgery, over 30 medical abstracts and presentations, and personally presented research involving steroid-eluting cardiac pacemaker wires at the 46th Annual Conference of the American Society for Artificial Internal Organs in New York, June 2000.
Blake remains closely involved with medicine in his practice which focuses on pharmaceutical litigation. Prior to coming to Clark, Love & Hutson, Blake was a member of a boutique litigation firm handling complex medical malpractice cases in Texas and Arkansas.
On November 18, 2013, along with Shelley Hutson, Blake obtained a $10,955,000 jury verdict in the second Topamax® birth defect case to be tried (Haley Powell, et al., Plaintiffs v. Janssen Pharmaceuticals, Inc., Defendant, Philadelphia County, Court of Common Pleas, Trial Division, May Term 2011, No. 02251). This case was designated by Janssen as a defense bellwether selection. Topamax® is an antiepileptic drug used to treat migraine headaches and epileptic seizures. It has long been recognized by Janssen that Topamax® could cause a wide variety of birth defects. Even though the company knew about these risks, Janssen failed to warn prescribing physicians and patients until the FDA required Janssen to change their label in 2011.
In addition to Blake's litigation practice, he has managed more than $720 million in various settlement programs for the firm.
Areas of Practice
- Pharmaceutical Litigation
- Products Liability
- Texas, 2004
- Pennsylvania, 2012
- U.S. District Court Southern District of Texas, 2005
- University of Houston Law Center, Houston, Texas
- J.D. - 2004
- Texas A&M University
- B.S. - 1998
- The Expert Report and Discovery Restrictions, 17th Annual Advanced Medical Malpractice Course, State Bar of Texas, 2010
- Vicarious and Direct Liability Claims, 17th Annual Advanced Medical Malpractice Course, State Bar of Texas, 2010
- Determining the Adequacy of the Expert Report, 17th Annual Advanced Medical Malpractice Course, State Bar of Texas, 2010
- Second Chances: 30 Day Extension to Cure Deficiencies in Expert Reports, 17th Annual Advanced Medical Malpractice Course, State Bar of Texas , 2010
Professional Associations and Memberships
- Texas Trial Lawyers Association